LGND Stock: Insider Activity, Filings & Research

Ligand Pharmaceuticals Incorporated (LGND) — Drillr’s hub for LGND insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, LGND insiders filed 0 open-market buys and 35 sales (SEC Form 4).

Over the trailing 90 days, insiders recorded 0 open-market purchases and 35 sales, a net selling of $5.3M. The largest was Espinoza Octavio (officer: Chief Financial Officer) selling $687.8K. The stock gained 12.2% over three months. Institutional holders were net accumulators over recent 13F filings. Insider sentiment scores 0/100.

Updated Jun 4, 2026 · based on SEC Form 4 filings · not investment advice

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$5.3M

Insider trades by month Buys Sells

Jan

Feb

Mar

Apr

May

Jun

Context3-month price +12.2%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Sell	200	$230.41
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Sell	1,216	$229.47
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Sell	1,432	$225.97
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Sell	584	$228.57
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Sell	677	$225.20
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Option	5,000	$52.27
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Sell	400	$226.78
Jun 2, 2026	Reardon Andrewofficer: CLO & Secretary	Sell	491	$223.95
May 28, 2026	Espinoza Octavioofficer: Chief Financial Officer	Option	972	$52.84
May 28, 2026	Espinoza Octavioofficer: Chief Financial Officer	Option	764	$63.62
May 14, 2026	KOZARICH JOHN Wdirector	Sell	1	$229.87
May 14, 2026	KOZARICH JOHN Wdirector	Sell	80	$227.37
May 14, 2026	KOZARICH JOHN Wdirector	Sell	459	$224.00
May 14, 2026	KOZARICH JOHN Wdirector	Sell	165	$231.87
May 14, 2026	KOZARICH JOHN Wdirector	Sell	1,575	$223.50

Source: LGND SEC Form 4 filings, latest Jun 2, 2026. For informational purposes only — not investment advice.

Overview

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biopharmaceutical company founded in 1987 and headquartered in Emeryville, California. The company went public in 1992 and has undergone significant strategic transformation over the past few years. Originally operating as a traditional biotechnology company with internal drug development programs, Ligand has evolved into a focused royalty and investment company that partners with pharmaceutical companies to develop and commercialize medicines. The company has streamlined its operations dramatically, reducing its workforce from 170 employees to approximately 35 while maintaining a lean, infrastructure-light business model centered on generating royalties from pharmaceutical products and investing in late-stage drug development opportunities.

Business

Ligand operates in the biopharmaceutical industry with a unique business model focused on three primary revenue streams. The company's core business involves acquiring royalty rights to pharmaceutical products and technologies, rather than developing drugs internally. **Royalty Business (Primary Revenue Driver - approximately 50-60% of total revenue):** Ligand owns royalty rights to over 90 pharmaceutical assets across various stages of development and commercialization. These include major commercial products such as Kyprolis (a multiple myeloma treatment), Filspari (for kidney diseases like IgA nephropathy), Ohtuvayre (a COPD treatment), and Capvaxive (a pneumococcal vaccine). The company receives percentage-based royalties on the net sales of these products, typically ranging from mid-single digits to low double digits. **Captisol Material Sales (approximately 20-25% of total revenue):** Ligand manufactures and sells Captisol, a proprietary solubility-enhancing technology that helps pharmaceutical companies improve the delivery and effectiveness of their drugs. Captisol is used in 16 FDA-approved products and serves as a critical excipient (inactive ingredient) that enables difficult-to-formulate drugs to be administered intravenously. The technology gained significant attention during the COVID-19 pandemic as it was used in Gilead's antiviral treatment Veklury (remdesivir). **Contract Revenue and Investment Income (approximately 15-25% of total revenue):** This segment includes milestone payments, licensing fees, and returns from the company's strategic investments in other biopharmaceutical companies. Ligand actively invests in late-stage drug development programs, providing capital in exchange for future royalty rights.

Revenue model

Ligand generates revenue through multiple complementary business models that create a diversified income stream. The company's primary revenue source comes from royalty payments based on the commercial success of pharmaceutical products developed by partner companies. These royalties are typically structured as percentage-based payments on net sales, providing Ligand with recurring revenue that scales with product success without requiring ongoing operational investment. The Captisol business operates on a traditional product sales model, where Ligand manufactures and sells the solubility-enhancing excipient to pharmaceutical companies for use in their drug formulations. This creates both one-time sales for research and development purposes and recurring revenue from commercial production. The company's investment strategy involves providing capital to biopharmaceutical companies in exchange for future royalty rights, milestone payments, or equity stakes. This approach allows Ligand to participate in the upside of successful drug development while diversifying risk across multiple programs. Several factors can significantly impact Ligand's margins and profitability. Positive margin drivers include the inherent scalability of royalty income (as partner products achieve greater commercial success, royalty payments increase without proportional cost increases), the company's lean operational structure with minimal ongoing R&D expenses, and the defensive nature of pharmaceutical demand. Negative margin pressures can arise from patent expirations on key royalty-generating products, competitive threats to partner products, regulatory setbacks affecting partner companies, and the cyclical nature of new drug approvals. Additionally, the company's investment returns can be volatile based on the clinical and commercial success of the programs it funds, and Captisol sales can fluctuate based on partner companies' manufacturing schedules and new product launches.

Risks & safety

Ligand demonstrates a strong margin of safety from a balance sheet perspective but faces earnings volatility typical of investment-focused businesses. **Liquidity and Solvency:** The company maintains excellent financial health with $72.3 million in cash and short-term investments as of Q1 2025, though this declined from previous quarters due to recent investments. Current ratio of 5.27 indicates strong short-term liquidity. Debt-to-equity ratio of 0.006 shows minimal leverage risk. **Cash Flow Characteristics:** Operating cash flow turned negative in Q1 2025 at -$25.4 million, primarily due to investment activities rather than operational losses. Free cash flow of -$25.7 million reflects the company's active investment phase. However, full-year 2024 showed strong positive operating cash flow of $97 million. **Valuation Metrics:** Trading at 2.54x book value and negative P/E due to recent losses from investment activities. EV/EBITDA is negative due to recent EBITDA losses, though the company projects return to profitability. **Other Considerations:** Revenue volatility from royalty timing and investment gains/losses creates earnings unpredictability. The company's lean operational structure provides cost flexibility, but investment returns remain inherently uncertain.

Recent development

Over the past few years, Ligand has undergone a dramatic strategic transformation from a traditional biotechnology company to a focused pharmaceutical royalty and investment firm. The most significant change involved spinning off its antibody discovery platforms (OmniAb and Pelican) and dramatically reducing its workforce from 170 employees to approximately 35, cutting operating expenses by over 50%. The company has aggressively pursued a buy-and-build royalty strategy, making several major investments including the $100 million acquisition of APEIRON Biologics (adding the Qarziba oncology drug royalty), a $50 million investment in Castle Creek Biosciences for D-Fi gene therapy, and various other late-stage pharmaceutical investments totaling over $200 million annually. This strategy has expanded Ligand's royalty-generating portfolio to over 90 assets across multiple therapeutic areas. Key product launches and approvals have driven recent growth, including FDA approvals for Ohtuvayre (COPD treatment), Capvaxive (pneumococcal vaccine), Filspari (kidney disease), and Zelsuvmi (molluscum contagiosum treatment). The company has also established Pathios Therapeutics as a subsidiary to develop and potentially spin out the Zelsuvmi asset. Ligand has strengthened its investment and business development capabilities by expanding its team in Boston and focusing on identifying high-value, late-stage pharmaceutical assets. The company typically targets investments of $30-40 million per opportunity, focusing on programs within four years of potential approval. Management projects achieving over $10 adjusted earnings per share by 2028, supported by a targeted royalty revenue compound annual growth rate exceeding 20%.

LGND company profile · for informational purposes only — not investment advice.

Track LGND with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free